Insulin pump or continuous subcutaneous insulin infusion (CSII) system is a widely adopted contemporary treatment for type 1 diabetes and is a major component of an artificial pancreas (AP). CSII accuracy is essential for glycemic control and to-date such metric has not been given sufficient study, especially at the range of the lowest basal rate. The gold-standard assessment method IEC (International Electrotechnical Commission) 60601-2-24 has some limitations. Our study presents a new accurate and reactive method for CSII system evaluation based on direct flow measurement. A leading-edge assessment method based on a double measurement approach utilizing a direct mass flow meter and a time-stamped microgravimetric bench test was combined with a Bayesian-based mathematical filter (Kalman). The performance of this new method was evaluated while assessing the delivery precision of an off-the-shelf insulin pump at several basal rates. The proposed methodology offers a double reading-volume and flow rate-which provides direct instantaneous flow rate. CSII dose errors were evaluated using mean absolute relative dispersion (MARD) at different time intervals windows over the whole test. The metrological aspect of the measurements and filtering performance were consistent. CSII precision is shown to be different in terms of the flow rate value: MARD (2 UI/h) = 12.7%, MARD (0.5 UI/h) = 20.4%, and MARD (0.1 UI/h) = 65.0%. MARD (2 UI/h) = 8.1%, (0.5 UI/h), MARD (0.5 UI/h) = 18.8%, and MARD (0.1 UI/h) = 18.4%. Instantaneous flow rate results highlight an irregular stroke-based delivery. This new method to assess insulin pump administration has been validated and highlights the current imprecision in insulin delivery, especially for the lowest basal rate, which is mainly used in pediatric cases and AP system delivery. This leading-edge method should be used to precisely compare several CSII performances in those contexts.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/dia.2019.0147 | DOI Listing |
Contact Dermatitis
January 2025
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
BMJ Case Rep
January 2025
Diabetes, Greenlane Hospital, Auckland, Auckland, New Zealand.
A woman in her 40s presented with severe post-bariatric hypoglycaemia that persisted despite nutritional therapy and pharmacological therapy with acarbose and subcutaneous octreotide with meals. The nutritional limitations were difficult to sustain, and she developed adverse effects to the pharmacological therapy, and hence, doses could not be increased. She was subsequently treated with subcutaneous octreotide via an insulin pump, with a continuous basal rate and additional bolus doses with meals.
View Article and Find Full Text PDFBMJ Open Diabetes Res Care
January 2025
Diabetes and Endocrinology, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
Introduction: The UK national pediatric diabetes audit reports higher HbA1c for children and young people (CYP) with type 1 diabetes (T1D) of Black ethnicity compared with White counterparts. This is presumably related to higher mean blood glucose (MBG) due to lower socioeconomic status (SES) and less access to technology. We aimed to determine if HbA1c ethnic disparity persists after accounting for the above variables.
View Article and Find Full Text PDFEndocr Pract
January 2025
University of Colorado Anschutz Medical Campus, Barbara Davis Center for Diabetes, 1775 Aurora Court, Aurora, CO 80045, USA. Electronic address:
Objectives: Type 1 diabetes (T1D) in pregnancy is challenging. This study explores how assisted hybrid closed-loop (HCL) therapy versus sensor-augmented pump therapy (SAPT) impacts quality of life (QoL) in pregnancy.
Methods: We interviewed 22 of 24 participants randomized to HCL therapy or SAPT in the Pregnancy Intervention with a Closed-Loop System study.
Diabet Med
January 2025
Steno Diabetes Center Copenhagen, Clinical Translational Research, Diabetes Technology Research, Herlev, Denmark.
Aims: This study was designed to compare the effectiveness of a single subcutaneous (s.c.) glucagon dose versus the same total dose split into a dose before and after and placebo (PBO) in preventing exercise-induced hypoglycaemia in adults with type 1 diabetes (T1D).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!